Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
about
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update.
P2860
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Gemcitabine plus cisplatin for ...... er prospective Phase II trial.
@en
type
label
Gemcitabine plus cisplatin for ...... er prospective Phase II trial.
@en
prefLabel
Gemcitabine plus cisplatin for ...... er prospective Phase II trial.
@en
P2093
P2860
P356
P1476
Gemcitabine plus cisplatin for ...... ter prospective Phase II trial
@en
P2093
Chang-Hsien Lu
Cheng-Hsu Wang
Cheng-Lung Hsu
Cheng-Ying Shiau
Chi-Huang Hsiao
Hung-Ming Wang
Jason Chia-Hsun Hsieh
Kuan-Der Lee
Ruey-Kuen Hsieh
Sheng-Yu Chen
P2860
P304
P356
10.1093/JJCO/HYV083
P50
P577
2015-06-08T00:00:00Z